1
|
Salem HF, Moubarak GA, Ali AA, Salama AAA, Salama AH. Budesonide-Loaded Bilosomes as a Targeted Delivery Therapeutic Approach Against Acute Lung Injury in Rats. J Pharm Sci 2023; 112:760-770. [PMID: 36228754 PMCID: PMC9549718 DOI: 10.1016/j.xphs.2022.10.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 10/02/2022] [Accepted: 10/02/2022] [Indexed: 11/17/2022]
Abstract
Budesonide (BUD), a glucocorticoids drug, inhibits all steps in the inflammatory response. It can reduce and treat inflammation and other symptoms associated with acute lung injury such as COVID-19. Loading BUD into bilosomes could boost its therapeutic activity, and lessen its frequent administration and side effects. Different bilosomal formulations were prepared where the independent variables were lipid type (Cholesterol, Phospholipon 80H, L-alpha phosphatidylcholine, and Lipoid S45), bile salt type (Na cholate and Na deoxycholate), and drug concentration (10, 20 mg). The measured responses were: vesicle size, entrapment efficiency, and release efficiency. One optimum formulation (composed of cholesterol, Na cholate, and 10 mg of BUD) was selected and investigated for its anti-inflammatory efficacy in vivo using Wistar albino male rats. Randomly allocated rats were distributed into four groups: The first: normal control group and received intranasal saline, the second one acted as the acute lung injury model received intranasal single dose of 2 mg/kg potassium dichromate (PD). Whereas the third and fourth groups received the market product (Pulmicort® nebulising suspension 0.5 mg/ml) and the optimized formulation (0.5 mg/kg; intranasal) for 7 days after PD instillation, respectively. Results showed that the optimized formulation decreased the pro-inflammatory cytokines TNF-α, and TGF-β contents as well as reduced PKC content in lung. These findings suggest the potentiality of BUD-loaded bilosomes for the treatment of acute lung injury with the ability of inhibiting the pro-inflammatory cytokines induced COVID-19.
Collapse
Affiliation(s)
- Heba F Salem
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
| | - Ghada Abdelsabour Moubarak
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ahram Canadian University, 6(th) of October City, Cairo, Egypt
| | - Adel A Ali
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
| | - Abeer A A Salama
- Pharmacology Department, National Research Centre, Dokki, Cairo 12622, Egypt
| | - Alaa H Salama
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ahram Canadian University, 6(th) of October City, Cairo, Egypt; Pharmaceutical Technology Department, National Research Centre, Dokki, Cairo 12622, Egypt.
| |
Collapse
|
2
|
Computed Tomography Image Segmentation of the Proximal Colon by U-Net for the Clinical Study of Somatostatin Combined with Intestinal Obstruction Catheter. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE 2022; 2022:6868483. [PMID: 35087602 PMCID: PMC8789412 DOI: 10.1155/2022/6868483] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 08/30/2021] [Accepted: 10/23/2021] [Indexed: 11/17/2022]
Abstract
Objective. U-Net technology is implemented for image segmentation to diagnose cases of intestinal obstruction. To evaluate the application value of somatostatin combined with transanal intestinal obstruction decompression catheter in the treatment of distal colonic malignant intestinal obstruction and to explore the therapeutic effect of somatostatin on acute abdomen surgery in patients with intestinal obstruction. Methods. After the segmentation technique, a retrospective analysis of 30 patients with acute and complete distal colonic malignant obstruction treated by surgery was divided into a control group and an observation group according to a random number table. The treatment efficiency, clinical symptoms, disappearance time after treatment, and the incidence of complications were compared between the two groups of patients. Results. The image segmentation using U-Net can effectively assist in the medical diagnosis of the colon. Our study found that patients with combined treatment with somatostatin and anal intestinal obstruction catheter were relieved of preoperative abdominal pain and abdominal distension; compared with the abdominal circumference at the time of admission, the abdominal circumference was significantly reduced. Abdominal examination was performed 3 days after comprehensive treatment, and combined with computed tomography (CT), we observed that the measured maximum transverse diameter of the proximal colon was significantly smaller than that before treatment. Before treatment, all patients were divided into a control group and a treatment group. After treatment, the symptoms of the two groups of patients were alleviated. The treatment effective rate of the observation group was 93.3%, and the treatment effective rate of the control group was 73.3%. The effective rate was significantly higher than that of the control group, and the difference was statistically significant. Conclusions. Through the use of image segmentation technology, somatostatin treatment of early inflammatory bowel obstruction after acute abdomen surgery can effectively improve the treatment efficiency of patients, shorten the disappearance of clinical symptoms, reduce the incidence of complications, and have a significant therapeutic effect, which is worthy of clinical application. Somatostatin combined with enteral obstruction catheter treatment is safe and effective for elderly patients with acute distal large bowel malignant intestinal obstruction. It has a higher completion rate of laparoscopic surgery and a first-stage anastomosis power, which reduces the risk of perioperative period and reduces the patient’s financial burden.
Collapse
|
3
|
Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity. Pharmaceutics 2022; 14:pharmaceutics14010131. [PMID: 35057027 PMCID: PMC8780659 DOI: 10.3390/pharmaceutics14010131] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 12/30/2021] [Accepted: 01/01/2022] [Indexed: 02/04/2023] Open
Abstract
This work aimed to optimize a celecoxib (CXB)-loaded solid lipid nanoparticles (SLN) colon delivery system for the enhancement of anticancer activity. An ultrasonic melt-emulsification method was employed in this work for the preparation of SLN. The physical attributes were characterized for their particle sizes, charges, morphology, and entrapment efficiency (%EE), in addition to DSC and FTIR. The in vitro drug release profiles were evaluated, and the anticancer activity was examined utilizing an MTT assay in three cancer cell lines: the colon cancer HT29, medulloblastoma Daoy, and hepatocellular carcinoma HepG2 cells. All of the prepared SLN formulations had nanoscale particle sizes ranging from 238 nm to 757 nm. High zeta-potential values (mv) within −30 s mv were reported. The %EE was in the range 86.76–96.6%. The amorphous nature of the SLN-entrapped CXB was confirmed from SLN DSC thermograms. The in vitro release profile revealed a slow constant rate of release with no burst release, which is unusual for SLN. Both the F9 and F14 demonstrated almost complete CXB release within 24 h, with only 25% completed within the first 5 h. F9 caused a significant percentage of cell death in the three cancer cell lines tested after 24 h of incubation and maintained this effect for 72 h. The prepared CXB-loaded SLN exhibited unique properties such as slow release with no burst and a high %EE. The anticancer activity of one formulation was extremely significant in all tested cancer cell lines at all incubation times, which is very promising.
Collapse
|
4
|
Lipid nanovesicles for biomedical applications: 'What is in a name'? Prog Lipid Res 2021; 82:101096. [PMID: 33831455 DOI: 10.1016/j.plipres.2021.101096] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 03/28/2021] [Accepted: 03/28/2021] [Indexed: 12/12/2022]
Abstract
Vesicles, generally defined as self-assembled structures formed by single or multiple concentric bilayers that surround an aqueous core, have been widely used for biomedical applications. They can either occur naturally (e.g. exosomes) or be produced artificially and range from the micrometric scale to the nanoscale. One the most well-known vesicle is the liposome, largely employed as a drug delivery nanocarrier. Liposomes have been modified along the years to improve physicochemical and biological features, resulting in long-circulating, ligand-targeted and stimuli-responsive liposomes, among others. In this process, new nomenclatures were reported in an extensive literature. In many instances, the new names suggest the emergence of a new nanocarrier, which have caused confusion as to whether the vesicles are indeed new entities or could simply be considered modified liposomes. Herein, we discussed the extensive nomenclature of vesicles based on the suffix "some" that are employed for drug delivery and composed of various types and proportions of lipids and others amphiphilic compounds. New names have most often been selected based on changes of vesicle lipid composition, but the payload, structural complexity (e.g. multicompartment) and new/improved proprieties (e.g. elasticity) have also inspired new vesicle names. Based on this discussion, we suggested a rational classification for vesicles.
Collapse
|
5
|
Sun Y, Li X, Zhang L, Liu X, Jiang B, Long Z, Jiang Y. Cell Permeable NBD Peptide-Modified Liposomes by Hyaluronic Acid Coating for the Synergistic Targeted Therapy of Metastatic Inflammatory Breast Cancer. Mol Pharm 2019; 16:1140-1155. [PMID: 30668131 DOI: 10.1021/acs.molpharmaceut.8b01123] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Chronic inflammation is closely related to the development, deterioration, and metastasis of tumors. Recently, many studies have shown that down-regulating the expression of inflammation by blocking nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3) pathways could significantly inhibit tumor growth and metastasis. The combined application of curcumin (CUR) and celecoxib (CXB) has been proven to exert a synergistic antitumor effect via inhibiting the activation of NF-κB and STAT3. TAT-NBD (TN) peptide, a fusion peptide of NF-κB essential modulator (NEMO)-binding domain peptide (NBD) and cell-penetrating peptide (TAT), can selectively block NF-κB activating pathway resulting in tumor growth inhibition. In the present study, a novel TN-modified liposome coloading both CXB and CUR (TN-CCLP) at a synergistic ratio was first constructed with the property of synchronous release, then hyaluronic acid (HA) as CD44 targeting moiety was coated on the surface of the cationic liposome via electrostatic interaction to prepare the anionic HA/TN-CCLP. In vitro results of cytotoxicity, macrophage migration inhibition, and anti-inflammation efficacy revealed that TN-CCLP and HA/TN-CCLP were significantly superior to TN-LP and CCLP, while TN-CCLP exhibited better effects than HA/TN-CCLP due to higher cellular uptake ability. Different from in vitro data, after systematically treating 4T1 breast tumor-bearing mice, HA/TN-CCLP exerted the most striking effects on anti-inflammation, inhibition of macrophage recruitment, and antitumor because of the longest circulation time and maximum tumor accumulation. In particular, HA/TN-CCLP could availably block the lung metastasis of breast cancer. Taken together, the novel CD44 targeted TN-CCLP exhibited the potential for inhibiting tumor development and metastasis through improving inflammatory infiltration of tumor tissue.
Collapse
Affiliation(s)
- Yuqing Sun
- Key Laboratory of Smart Drug Delivery, Ministry of Education (Fudan University), Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 200032 , China
| | - Xuqian Li
- Key Laboratory of Smart Drug Delivery, Ministry of Education (Fudan University), Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 200032 , China
| | - Lili Zhang
- School of Pharmacy , Shanghai University of Traditional Chinese Medicine , Shanghai 201203 , China
| | - Xiao Liu
- Key Laboratory of Smart Drug Delivery, Ministry of Education (Fudan University), Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 200032 , China
| | - Baohong Jiang
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203 , China
| | - Zhiguo Long
- Department of Hematology, Shanghai Pudong Hospital , Fudan University , Shanghai 201399 , China
| | - Yanyan Jiang
- Key Laboratory of Smart Drug Delivery, Ministry of Education (Fudan University), Department of Pharmaceutics, School of Pharmacy , Fudan University , Shanghai 200032 , China
| |
Collapse
|
6
|
Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target 2018; 27:742-761. [PMID: 30239255 DOI: 10.1080/1061186x.2018.1527337] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
In the last decades, pharmaceutical interested researches aimed to develop novel and innovative drug delivery techniques in the medical and pharmaceutical fields. Recently, phospholipid vesicles (Liposomes) are the most known versatile assemblies in the drug delivery systems. The discovery of liposomes arises from self-forming enclosed phospholipid bilayer upon coming in contact with the aqueous solution. Liposomes are uni or multilamellar vesicles consisting of phospholipids produced naturally or synthetically, which are readily non-toxic, biodegradable, and are readily produced on a large scale. Various phospholipids, for instance, soybean, egg yolk, synthetic, and hydrogenated phosphatidylcholine consider the most popular types used in different kinds of formulations. This review summarises liposomes composition, characterisation, methods of preparation, and their applications in different medical fields including cancer therapy, vaccine, ocular delivery, wound healing, and some dermatological applications.
Collapse
Affiliation(s)
- Kamel S Ahmed
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Jiangnan University , Wuxi , PR China.,b Department of Pharmaceutics , Faculty of Pharmacy, Minia University , Minia , Egypt
| | - Saied A Hussein
- c Department of Biomedical Engineering , College of Life Science and Technology, Huazhong University of Science and Technology , Wuhan , PR China
| | - Abdelmoneim H Ali
- d State Key Laboratory of Food Science and Technology, Synergetic Innovation Center of Food Safety and Nutrition, School of Food Science and Technology, Jiangnan University , Wuxi , PR China
| | - Sameh A Korma
- d State Key Laboratory of Food Science and Technology, Synergetic Innovation Center of Food Safety and Nutrition, School of Food Science and Technology, Jiangnan University , Wuxi , PR China
| | - Qiu Lipeng
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Jiangnan University , Wuxi , PR China
| | - Chen Jinghua
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Jiangnan University , Wuxi , PR China
| |
Collapse
|
7
|
Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation. Int J Pharm 2018; 540:89-97. [DOI: 10.1016/j.ijpharm.2018.01.039] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 01/19/2018] [Accepted: 01/21/2018] [Indexed: 01/14/2023]
|
8
|
López-Dávila V, Magdeldin T, Welch H, Dwek MV, Uchegbu I, Loizidou M. Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro model. Nanomedicine (Lond) 2016; 11:331-44. [PMID: 26786002 DOI: 10.2217/nnm.15.206] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
AIM In this work, we use cationic organic nanocarriers as chemotherapy delivery platforms and test them in a colorectal cancer 3D in vitro model. MATERIALS & METHODS We used 3beta-(N-[N',N'-dimethylaminoethane]carbamoyl])cholesterol (DC-chol) and dioleoylphosphatidylethanolamine (DOPE) liposomes and N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ) micelles, to deliver AZD6244, a MEK inhibitor, to HCT116 cells cultured as monolayers and in 3D in vitro cancer models (tumoroids). RESULTS Nanoparticle-mediated drug delivery was superior to the free drug in monolayer experiments and despite their therapeutic effect being hindered by poor diffusion through the cancer mass, GCPQ micelles were also superior in tumoroids. CONCLUSION These results support the role of nanoparticles in improving drug delivery and highlight the need to include 3D cancer models in early phases of drug development.
Collapse
Affiliation(s)
- Víctor López-Dávila
- Cancer Nanotechnology Group, University College London, Division of Surgery & Interventional Science, Royal Free Campus, London, NW3 2PF, UK
| | - Tarig Magdeldin
- Cancer Nanotechnology Group, University College London, Division of Surgery & Interventional Science, Royal Free Campus, London, NW3 2PF, UK.,Institute of Orthopaedics & Musculoskeletal Sciences, University College London, Division of Surgery & Interventional Science, Stanmore Campus, HA7 4LP, UK
| | - Hazel Welch
- Cancer Nanotechnology Group, University College London, Division of Surgery & Interventional Science, Royal Free Campus, London, NW3 2PF, UK
| | - Miriam Victoria Dwek
- Department of Biomedical Sciences, Faculty of Science & Technology, University of Westminster, 115 New Cavendish Street, London, W1W 6UW, UK
| | - Ijeoma Uchegbu
- School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK
| | - Marilena Loizidou
- Cancer Nanotechnology Group, University College London, Division of Surgery & Interventional Science, Royal Free Campus, London, NW3 2PF, UK
| |
Collapse
|
9
|
Limasale YDP, Tezcaner A, Özen C, Keskin D, Banerjee S. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. Int J Pharm 2015; 479:364-73. [PMID: 25595386 DOI: 10.1016/j.ijpharm.2015.01.016] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Revised: 01/07/2015] [Accepted: 01/10/2015] [Indexed: 12/14/2022]
Abstract
Cyclooxygenase-2 (COX-2) is highly expressed in many different cancers. Therefore, the inhibition of the COX-2 pathway by a selective COX-2 inhibitor, celecoxib (CLX), may be an alternative strategy for cancer prevention and therapy. Liposomal drug delivery systems can be used to increase the therapeutic efficacy of CLX while minimizing its side effects. Previous studies have reported the encapsulation of CLX within the non-targeted long circulating liposomes and functional effect of these formulations against colorectal cancer cell lines. However, the selectivity and internalization of CLX-loaded liposomes can further be improved by grafting targeting ligands on their surface. Cetuximab (anti-epidermal growth factor receptor - EGFR - monoclonal antibody) is a promising targeting ligand since EGFR is highly expressed in a wide range of solid tumors. The aim of this study was to develop EGFR-targeted immunoliposomes for enhancing the delivery of CLX to cancer cells and to evaluate the functional effects of these liposomes in cancer cell lines. EGFR-targeted ILs, having an average size of 120nm, could encapsulate 40% of the CLX, while providing a sustained drug release profile. Cell association studies have also shown that the immunoliposome uptake was higher in EGFR-overexpressing cells compared to the non-targeted liposomes. In addition, the CLX-loaded-anti-EGFR immunoliposomes were significantly more toxic compared to the non-targeted ones in cancer cells with EGFR-overexpression but not in the cells with low EGFR expression, regardless of their COX-2 expression status. Thus, selective targeting of CLX with anti-EGFR immunoliposomes appears to be a promising strategy for therapy of tumors that overexpress EGFR.
Collapse
Affiliation(s)
| | - Ayşen Tezcaner
- Department of Biotechnology, Middle East Technical University, Ankara 06800, Turkey; Department of Engineering Sciences, Middle East Technical University, Ankara 06800, Turkey; BIOMATEN, Center of Excellence in Biomaterials and Tissue Engineering, Middle East Technical University, Ankara 06800, Turkey
| | - Can Özen
- Department of Biotechnology, Middle East Technical University, Ankara 06800, Turkey; BIOMATEN, Center of Excellence in Biomaterials and Tissue Engineering, Middle East Technical University, Ankara 06800, Turkey
| | - Dilek Keskin
- Department of Biotechnology, Middle East Technical University, Ankara 06800, Turkey; Department of Engineering Sciences, Middle East Technical University, Ankara 06800, Turkey; BIOMATEN, Center of Excellence in Biomaterials and Tissue Engineering, Middle East Technical University, Ankara 06800, Turkey
| | - Sreeparna Banerjee
- Department of Biotechnology, Middle East Technical University, Ankara 06800, Turkey; Department of Biological Sciences, Middle East Technical University, Ankara 06800, Turkey.
| |
Collapse
|